Floatz logo

Sgm-101

Liver Metastasis Colon Cancer

Leiden University Medical CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Liver Metastasis Colon Cancer cohort.

Asset / SponsorPhaseRating
Eloxatin
Fudan University
Phase 4BBB
Fruquintinib
Peking University
Phase 3BBB
DEXAMETHASONE
Fudan University
Phase 3BB
Capecitabine
Jun Huang
Phase 3BB
Irinotecan
Jun Huang
Phase 3BB

View all 50 →

Same molecule, other indications

Sgm-101 is also rated in:

rectal cancerDormant
BB
Indicative ·
64 / 100
View asset →
colorectal neoplasmDormant
B
Indicative ·
59 / 100
View asset →
metastasis from malignant tumor of colonDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →